Author:
Gerashchenko I. I., ,Stepanyuk K. O.,Chepliaka O. M.,Borysenko M. V.,Pakhlov E. M.,Klyuchkov D. G.,Vinogradova K. G., , , , , ,
Abstract
Неaling of infected ulcers and wounds, particularly in older people, is a serious problem in modern surgery. As a result of many years efforts, we have created an innovative wound care composition that has high absorptive, anti-inflammatory and wound-healing capabilities and are starting the clinical study of it. The composition, which got a trade mark Pathelen®, contains nanoscale hydrophilic silica (A-300), hydrophobic silica (Aerosil® R972 Pharma) and benzalkonium chloride. This work aimed to develop an optimal pathway of industrial production, as well as methods of quality control of the drug. The examination of manufacture intermediates and the final product includes bulk density measurement, thermal analysis, IR spectroscopy, chemical methods of identification, adsorption capacity and microbial contamination control. The pathway of manufacture which consists of mechanochemical immobilization of benzalkonium chloride on hydrophobic silica surface and mixing of obtained semi-product with hydrophilic nanoscale silica is developed. Thus, a technological method is proposed for combining hydrophilic and hydrophobic nanomaterials in one preparation. The final product complies to the elaborated quality parameters. In particular, the bulk density is distributed in a range 50–60 g/L, the adsorption capacity is not less than 140 mg of protein per gram. The absence of pathogenic microorganisms and fungi was demonstrated; the quantity of non-pathogenic microorganisms meets the requirements of the European Pharmacopoeia for products in this category. The results obtained can be useful for the organization a large-scale production of the proposed drug in future.
Publisher
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Subject
Materials Chemistry,Colloid and Surface Chemistry,Physical and Theoretical Chemistry,Surfaces, Coatings and Films,Surfaces and Interfaces,Ceramics and Composites
Reference17 articles.
1. 1. Boulton A.J., Vileikyte L., Ragnarson-Tennvall G., Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005. 366(9498): 1719.
2. 2. International Working group on the Diabetic Foot (IWGDF). The development of global consensus guidelines on the management and prevention of the Diabetic Foot. 2015. http:// www.iwgdf.org
3. 3. Huang S.S., Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin. Infect. Dis. 2003. 36(3): 281.
4. 4. Kaye K.S., Anderson D.J., Choi Y., Link K., Thacker P., Sexton D.J. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin. Infect. Dis. 2008. 46(10): 1568.
5. 5. Cooney D.O. Activated charcoal in medical applications. In: Informa healthcare. 2nd ed. (New York-London: CRC Press, 1995).